AUS
NZ
UK
CA
USA
IND
Highlights
-
Graft Polymer (UK) PLC is advancing a preclinical program focused on mental health conditions, particularly post-traumatic stress disorder (PTSD), in collaboration with Eurofins Discovery.
-
The company is testing its co-lead aminoindane series, designed to interact with serotonin, dopamine, and norepinephrine receptors to mitigate the human response to trauma.
-
CEO Anthony Tennyson emphasized the significant unmet need in PTSD treatment, noting that there are approximately 13 million sufferers in the U.S. alone, and Graft Polymer anticipates preclinical results by the end of November.
In a recent discussion with Proactive’s Stephen Gunnion, Graft Polymer (UK) PLC {LSE:GPL} CEO Anthony Tennyson highlighted the company's promising preclinical program aimed at addressing mental health conditions, specifically post-traumatic stress disorder (PTSD). Collaborating with Eurofins Discovery, Graft Polymer is currently evaluating its co-lead aminoindane series, a novel class of compounds that target serotonin, dopamine, and norepinephrine receptors to potentially alleviate trauma responses.
Tennyson noted the pervasive impact of PTSD, stating, “Unfortunately, PTSD affects millions, with 13 million sufferers in the U.S. alone.” He emphasized that existing treatment options are limited, creating a substantial addressable market for effective solutions. The partnership with Eurofins Discovery, known for its expertise in research services, is expected to expedite the development process, positioning Graft Polymer to make significant advancements in PTSD treatment.
The company is optimistic about the preclinical results, which are anticipated by the end of November. This timeline suggests a rapid progression in their research efforts, potentially paving the way for novel therapeutic approaches to combat PTSD and improve the quality of life for millions affected by this condition. Graft Polymer’s focus on addressing such an unmet need underscores its commitment to innovation in mental health treatments.
